[go: up one dir, main page]

SG11201911617SA - T cells with reduced surface fucosylation and methods of making and using the same - Google Patents

T cells with reduced surface fucosylation and methods of making and using the same

Info

Publication number
SG11201911617SA
SG11201911617SA SG11201911617SA SG11201911617SA SG11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA
Authority
SG
Singapore
Prior art keywords
cells
making
methods
same
reduced surface
Prior art date
Application number
SG11201911617SA
Inventor
Nicole Okeley
Jessica Field
Shyra Gardai
Ryan Heiser
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201911617SA publication Critical patent/SG11201911617SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
SG11201911617SA 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same SG11201911617SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516536P 2017-06-07 2017-06-07
PCT/US2018/036067 WO2018226701A1 (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Publications (1)

Publication Number Publication Date
SG11201911617SA true SG11201911617SA (en) 2020-01-30

Family

ID=62751563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911617SA SG11201911617SA (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Country Status (17)

Country Link
US (2) US11891644B2 (en)
EP (1) EP3634427A1 (en)
JP (1) JP7245177B2 (en)
KR (1) KR102687149B1 (en)
CN (1) CN110740734A (en)
AU (1) AU2018282225B2 (en)
BR (1) BR112019025775A2 (en)
CA (1) CA3065524A1 (en)
EA (1) EA201992875A1 (en)
IL (1) IL271012B2 (en)
MA (1) MA50865A (en)
MX (1) MX2019014584A (en)
SG (1) SG11201911617SA (en)
TW (1) TW201903144A (en)
UA (1) UA128783C2 (en)
WO (1) WO2018226701A1 (en)
ZA (1) ZA201907623B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220305038A1 (en) * 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US20240197761A1 (en) * 2021-04-16 2024-06-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP2608796B1 (en) 2010-08-05 2018-11-21 Seattle Genetics, Inc. Inhibition of protein fucosylation in vivo using fucose analogs
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
KR20160113295A (en) 2014-02-04 2016-09-28 카이트 파마 인코포레이티드 Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MX2017000646A (en) 2014-07-15 2017-04-27 Juno Therapeutics Inc GENETICALLY MODIFIED CELLS FOR ADOPTIVE CELL THERAPY.
MX2017003062A (en) 2014-09-09 2017-12-14 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy.
KR102804498B1 (en) 2014-12-03 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 Methods and compositions for adoptive cell therapy
KR20250089563A (en) 2015-10-20 2025-06-18 카이트 파마 인코포레이티드 Methods of preparing t cells for t cell therapy
WO2017096274A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Also Published As

Publication number Publication date
BR112019025775A2 (en) 2020-06-23
IL271012B2 (en) 2023-12-01
US11891644B2 (en) 2024-02-06
JP7245177B2 (en) 2023-03-23
CN110740734A (en) 2020-01-31
TW201903144A (en) 2019-01-16
KR102687149B1 (en) 2024-07-24
US20240117400A1 (en) 2024-04-11
JP2020523014A (en) 2020-08-06
CA3065524A1 (en) 2018-12-13
KR20200015580A (en) 2020-02-12
MA50865A (en) 2020-04-15
EA201992875A1 (en) 2020-03-25
IL271012A (en) 2020-01-30
AU2018282225B2 (en) 2024-06-13
EP3634427A1 (en) 2020-04-15
ZA201907623B (en) 2024-04-24
UA128783C2 (en) 2024-10-23
AU2018282225A1 (en) 2019-12-12
IL271012B1 (en) 2023-08-01
MX2019014584A (en) 2020-02-07
WO2018226701A1 (en) 2018-12-13
US20200149082A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
EP3601528A4 (en) Cells and methods of uses and making the same
IL254734A0 (en) Modified t cells and methods of making and using the same
IL276515B2 (en) Pd-l1-specific antibodies and methods of using the same
SG11202004116QA (en) T cell manufacturing compositions and methods
EP3231024A4 (en) Electrochemical cell and method of making the same
CA3246817A1 (en) Graft with expandable region and methods of making and using the same
IL255801A (en) Liposomal nanoconstructs and methods of making and using the same
EP3093889B8 (en) Solar cell and method of manufacturing the same
EP3619301A4 (en) Neurotransmitters and methods of making the same
EP3250682A4 (en) Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP3380577A4 (en) Coated particles and methods of making and using the same
SG11202012253WA (en) Nef-containing t cells and methods of producing thereof
EP3218477A4 (en) Compositions and methods for expressing polypeptides on the surface of cells
PL3443608T3 (en) Electrochemical cells having designed flow fields and methods for producing the same
SG11201900459RA (en) Mg53 mutants, methods of making the same, and uses thereof
EP3096892A4 (en) Carbon nanotube-coated substrates and methods of making the same
IL250554A0 (en) Improved osteoinductive substrates and methods of making the same
EP3307873A4 (en) Hematopoietic cells and methods of using and generating the same
EP3494217A4 (en) Lmp1-expressing cells and methods of use thereof
EP3096742A4 (en) Compositions and methods for modifying the surface of cells and methods of use
SG11201911617SA (en) T cells with reduced surface fucosylation and methods of making and using the same
EP3651606A4 (en) Gemstone coatings and methods of making and using the same
EP3515207A4 (en) Natural water essence and methods of making the same
EP3334730A4 (en) Pyrrolomycins and methods of using the same
EP3294763A4 (en) Glucanase production and methods of using the same